"HIV-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
| Descriptor ID |
D015497
|
| MeSH Number(s) |
B04.820.650.589.650.350.400
|
| Concept/Terms |
HIV-1- HIV-1
- Human immunodeficiency virus 1
- HIV-I
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1
|
Below are MeSH descriptors whose meaning is more general than "HIV-1".
Below are MeSH descriptors whose meaning is more specific than "HIV-1".
This graph shows the total number of publications written about "HIV-1" by people in this website by year, and whether "HIV-1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 6 | 1 | 7 |
| 1995 | 2 | 4 | 6 |
| 1996 | 1 | 2 | 3 |
| 1997 | 4 | 0 | 4 |
| 1998 | 2 | 2 | 4 |
| 1999 | 3 | 0 | 3 |
| 2000 | 3 | 1 | 4 |
| 2001 | 2 | 1 | 3 |
| 2002 | 4 | 1 | 5 |
| 2003 | 3 | 1 | 4 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 5 | 0 | 5 |
| 2007 | 5 | 1 | 6 |
| 2008 | 5 | 2 | 7 |
| 2009 | 5 | 2 | 7 |
| 2010 | 2 | 0 | 2 |
| 2011 | 5 | 2 | 7 |
| 2012 | 3 | 6 | 9 |
| 2013 | 3 | 0 | 3 |
| 2014 | 3 | 0 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 7 | 1 | 8 |
| 2017 | 4 | 3 | 7 |
| 2018 | 8 | 0 | 8 |
| 2019 | 3 | 2 | 5 |
| 2020 | 4 | 1 | 5 |
| 2021 | 4 | 1 | 5 |
| 2022 | 2 | 0 | 2 |
| 2023 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV-1" by people in Profiles.
-
Antiviral HIV-1 SERINC restriction factors disrupt virus membrane asymmetry. Nat Commun. 2023 07 20; 14(1):4368.
-
Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis. AIDS. 2023 09 01; 37(11):1711-1714.
-
HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell. 2023 03 16; 186(6):1115-1126.e8.
-
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial. Clin Infect Dis. 2023 02 18; 76(4):720-729.
-
Prevalence of HIV-1 Natural Polymorphisms and Integrase-Resistance-Associated Mutations in African Children. Viruses. 2023 02 16; 15(2).
-
Utility of the Signal-to-Cutoff Ratio and Antigen Index from Fourth- and Fifth-Generation HIV-1/HIV-2 Antigen/Antibody Assays for the Diagnosis of Acute HIV Infection: Applicability for Real-Time Use for Immediate Initiation of Antiretroviral Therapy. J Clin Microbiol. 2022 12 21; 60(12):e0120422.
-
A highly virulent variant of HIV-1 circulating in the Netherlands. Science. 2022 02 04; 375(6580):540-545.
-
COVID-19-Related Stressors, Sex Behaviors, and HIV Status Neutral Care Among Black Men Who Have Sex With Men and Transgender Women in Chicago, USA. J Acquir Immune Defic Syndr. 2021 11 01; 88(3):261-271.
-
A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response. Nat Genet. 2021 10; 53(10):1504-1516.
-
Two-drug HIV regimens: more data still needed. Lancet HIV. 2021 08; 8(8):e454-e455.